R. Maymon et al., Serum inhibin A levels in pregnant women with systemic lupus erythematosusor antiphospholipid syndrome, PRENAT DIAG, 20(1), 2000, pp. 12-16
Citations number
25
Categorie Soggetti
Reproductive Medicine","Medical Research Diagnosis & Treatment
Maternal serum inhibin a levels are increased on average in pregnancies aff
ected by Down syndrome (DS). However, some reports have found increased ser
um levels in women with pre-eclamptic toxaemia as well. In the current stud
y, maternal serum inhibin A was retrospectively measured in a series of 32
serum samples from pregnant women previously diagnosed as having either sys
temic lupus erythematosus (SLE) or primary antiphospholipid syndrome (APS).
For comparison, normal medians were calculated from 57 unaffected control
pregnancies together with a total Of 854 samples tested at 13-19 weeks of g
estation as part of the routine antenatal DS screening. All results were ex
pressed in multiples of the gestation specific normal medians (MoM). A cubi
c regression formula was fitted, weighting for the number of women tested a
t each gestation. The median MoM value in the 16 cases of SLE and the 16 ca
ses of primary APS is 0.60 (95%, confidence interval 0.40-0.91) and 0.8& (9
5% confidence interval 0.66-1.17), respectively. For primary APS this was n
ot statistically significant, whereas the SLE patients had a highly statist
ically significant reduction of serum inhibin a (p<0.002, Wilcoxon Rank sum
Test, 2 tailed). Six pregnancies in the SLE group had a complicated obstet
ric outcome, i.e, missed abortion, placental abruption, exacerbation of the
underlying disease which necessitated delivery, and severe postpartum haem
orrhage. In 85% of this subgroup, serum inhibin A levels were below the nor
mal 10th centile. The current data suggest that serum inhibin A is dea ease
d on average in SLE patients. Those preliminary results might have various
obstetric implications such as antenatal DS screening of SLE patients, iden
tification of pregnant women at risk of developing SLE, who have presented
for routine DS screening and for monitoring SLE patients throughout their p
regnancy. Copyright (C) 2000 John Wiley & Sons, Ltd.